Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesMulticenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas
Journal of Clinical Oncology, 07/01/09
George S et al. - Sunitinib demonstrated notable evidence of metabolic response in several patients with non-GIST sarcoma. The relevance of disease control observed in subtypes with an indolent natural history is unknown, however, the durable disease control observed in DSRCT, solitary fibrous tumor, and giant cell tumor of bone suggests that future evaluation of sunitinib in these subtypes may be warranted.
Related Articles
Coincident expression of beta-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas
Modern Pathology, 11/11/09
Relevance Score: 92%
Histiocytic sarcoma with interdigitating dendritic cell differentiation: A case report with fine needle aspiration cytology and review of literature
Diagnostic Cytopathology, 10/28/09
Relevance Score: 90%
Skeletal metastasis from sarcoma: a report of three cases
European Journal of Orthopaedic Surgery & Traumatology, 10/23/09
Relevance Score: 89%
Alveolar soft-part sarcoma of the tongue in a 17-month-old
ENT Journal, 10/19/09
Relevance Score: 89%
Radiological assessment following thermoradiation therapy for primary pleural synovial sarcoma: case report
Medical Oncology, 10/19/09
Relevance Score: 89%
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Zoledronic acid: an unending tale for an antiresorptive agent
Expert Opinion in Pharmacotherapy, 12/11/09
HER-2 targeted treatment of osteosarcoma: the challenges of developing targeted therapy and prognostic factors for rare malignancies
Expert Opinion in Pharmacotherapy, 12/11/09
Risk of additional cancers in untreated and treated hairy cell leukemia patients
Expert Opinion in Pharmacotherapy, 12/11/09
Sponsor
Article Search
Sponsor
Sponsor